Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial

被引:156
|
作者
Agahi, Azadeh [1 ]
Hamidi, Gholam Ali [1 ]
Daneshvar, Reza [2 ]
Hamdieh, Mostafa [3 ]
Soheili, Masoud [1 ]
Alinaghipour, Azam [1 ]
Taba, Seyyed Mohammad Esmaeili [4 ]
Salami, Mahmoud [1 ]
机构
[1] Kashan Univ Med Sci, Physiol Res Ctr, Kashan, Iran
[2] Kashan Univ Med Sci, Dept Neurol, Sch Med, Kashan, Iran
[3] Shaheed Beheshti Univ Med Sci, Sch Med, Dept Psychol, Tehran, Iran
[4] Farhangian Univ, Dept Educ, Taleghani Branch, Qom, Iran
来源
FRONTIERS IN NEUROLOGY | 2018年 / 9卷
关键词
probiotics; Alzheimer's disease; cognition; inflammation; oxidative stress; microbiota; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PROBIOTIC SUPPLEMENTATION; MULTIPLE-SCLEROSIS; EXPRESSION; INTERLEUKIN-6; INFLAMMATION; PROTEIN; HEALTH; MEMORY;
D O I
10.3389/fneur.2018.00662
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease (AD) is associated with cognitive dysfunction. Evidence indicates that gut microbiota is altered in the AD and, hence, modifying the gut flora may affect the disease. In the previous clinical research we evaluated the effect of a probiotic combination on the cognitive abilities of AD patients. Since, in addition to pathological disorders, the AD is associated with changes in oxidant/antioxidant and inflammatory/anti-inflammatory biomarkers, the present work was designed to evaluate responsiveness of the inflammatory and oxidative biomarkers to the probiotic treatment. The control (CON) and probiotic (PRO) AD patients were treated for 12 weeks by the placebo and probiotic supplementation, respectively. The patients were cognitively assessed by Test Your Memory (TYM = 50 scores). Also serum concentrations of nitric oxide (NO), glutathione (GSH), total antioxidant capacity (TAC), malondialdehyde (MDA), 8-hydroxy-2'-deoxyguanosine (8-OHdG) and cytokines (TNF-a, IL-6, and IL-10) were measured. The cognitive test and the serum biomarkers were assessed pre- and post-treatment. According to TYM test 83.5% of the patients showed severe AD. The CON (12.86% +/- 8.33) and PRO (-9.35% +/- 16.83) groups not differently scored the cognitive test. Not pronounced change percent was found in the serum level of TNF-alpha (1.67% +/- 1.33 vs. -0.15% +/- 0.27), IL-6 (0.35% +/- 0.17 vs. 2.18% +/- 0.15), IL-10 (0.05% +/- 0.10 vs. -0.70% +/- 0.73), TAC (0.07% +/- 0.07 and -0.06% +/- 0.03), GSH (0.08% +/- 0.05 and 0.04% +/- 0.03) NO (0.11% +/- 0.06 and 0.05% +/- 0.09), MDA (-0.11% +/- 0.03 and -0.17% +/- 0.03), 8-OHdG (43.25% +/- 3.01 and 42.70% +/- 3.27) in the CON and PRO groups, respectively. We concluded that the cognitive and biochemical indications in the patients with severe AD are insensitive to the probiotic supplementation. Therefore, in addition to formulation and dosage of probiotic bacteria, severity of disease and time of administration deeply affects results of treatment.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Plasma metabolites of aromatic amino acids associate with clinical severity and gut microbiota of Parkinson's disease
    Chen, Szu-Ju
    Wu, Yu-Jun
    Chen, Chieh-Chang
    Wu, Yu-Wei
    Liou, Jyh-Ming
    Wu, Ming-Shiang
    Kuo, Ching-Hua
    Lin, Chin-Hsien
    NPJ PARKINSONS DISEASE, 2023, 9 (01)
  • [22] A double blind, placebo-controlled, phase II clinical trial of intravenous immunoglobulin (IVIG) for treatment of Alzheimer's disease
    Relkin, Norman
    Tsakanikas, Diamonte I.
    Adamiak, Basia
    Assuras, Stephanie
    Shenoy, Sushila
    Flores, Carolina
    Shah, Kavita
    Ravdin, Lisa D.
    Szabo, Paul
    Weksler, Marc
    NEUROLOGY, 2008, 70 (11) : A393 - A393
  • [23] Alzheimer's disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence
    Mancuso, Cesare
    Santangelo, Rosaria
    PHARMACOLOGICAL RESEARCH, 2018, 129 : 329 - 336
  • [24] Efficacy of acupuncture in patients with mild Alzheimer's disease and its impact on gut microbiota: Study protocol for a randomized sham-controlled trial
    Kong, Xiehe
    Ma, Zhao
    Tang, Ran
    Wang, Xuejun
    Wei, Kai
    Yang, Guang
    Yang, Yanting
    Zhao, Yue
    Zhang, Dan
    Xie, Chen
    Wang, Gang
    Ma, Xiaopeng
    FRONTIERS IN MEDICINE, 2023, 10
  • [25] DOES SEROTONIN AUGMENTATION HAVE ANY EFFECT ON COGNITION AND ACTIVITIES OF DAILY LIVING IN ALZHEIMER'S DEMENTIA?: A DOUBLE-BLIND CLINICAL TRIAL
    Mowla, A.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [26] Cilostazol in Raynaud s disease: A double-blind placebo controlled clinical trial
    Rajagopalan, S
    Pfenninger, D
    Kehrer, C
    Somers, E
    Chakraborti, A
    McCune, WJ
    Mukherjee, D
    Brook, RD
    Kaplan, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 304A - 304A
  • [27] Does the change in glutamate to GABA ratio correlate with change in depression severity? A randomized, double-blind clinical trial
    Narayan, G. Anjali
    Hill, Kathryn R.
    Wengler, Kenneth
    He, Xiang
    Wang, Junying
    Yang, Jie
    Parsey, Ramin, V
    DeLorenzo, Christine
    MOLECULAR PSYCHIATRY, 2022, 27 (09) : 3833 - 3841
  • [28] Does the change in glutamate to GABA ratio correlate with change in depression severity? A randomized, double-blind clinical trial
    G. Anjali Narayan
    Kathryn R. Hill
    Kenneth Wengler
    Xiang He
    Junying Wang
    Jie Yang
    Ramin V. Parsey
    Christine DeLorenzo
    Molecular Psychiatry, 2022, 27 : 3833 - 3841
  • [29] Repetitive transcranial magnetic stimulation as a treatment for Alzheimer's disease: A randomized placebo-controlled double-blind clinical trial
    Moussavi, Zahra
    Uehara, Maria
    Rutherford, Grant
    Lithgow, Brian
    Millikin, Colleen
    Wang, Xikui
    Saha, Chandan
    Mansouri, Behzad
    Omelan, Craig
    Fellows, Lesley
    Fitzgerald, Paul B.
    Koski, Lisa
    NEUROTHERAPEUTICS, 2024, 21 (03)
  • [30] Neurostimulation Combined With Cognitive Intervention in Alzheimer's Disease (NeuroAD): Study Protocol of Double-Blind, Randomized, Factorial Clinical Trial
    Andrade, Suellen Marinho
    de Oliveira, Eliane Araujo
    Alves, Nelson Torro
    Gomes dos Santos, Ana Cristina
    Ponce Leon de Mendonca, Camila Teresa
    Amorim Sampaio, Danielle Dorand
    Querino Cavalcante da Silva, Edyllaine Elidy
    Goncalves da Fonseca, Egina Karoline
    de Almeida Rodrigues, Evelyn Thais
    Siqueira de Lima, Gabriela Nayara
    Carvalho, Jamerson
    Silvestre da Silva, Jessyca Alves
    Toledo, Manuella
    Diniz da Rosa, Marine Raquel
    de Carvalho Gomes, Marcia Queiroz
    de Oliveira, Melquisedek Monteiro
    Maia Lemos, Moema Teixeira
    Lima, Nagylla Gomes
    Inacio, Penha
    da Cruz Ribeiro e Rodrigues, Petra Maria
    Dantas Ferreira, Rayssa Gabriela
    Cavalcante, Renata
    Lyra de Brito Aranha, Renata Emanuela
    Neves, Regina
    da Costa e Souza, Rodrigo Marmo
    Portugal, Thaina Magalhaes
    Nascimento Martins, Wanessa Kallyne
    Pontes, Vivian
    de Paiva Fernandes, Thiago Monteiro
    Contador, Israel
    Fernandez-Calvo, Bernardino
    FRONTIERS IN AGING NEUROSCIENCE, 2018, 10